Anteris Technologies

Anteris Technologies is a global structural heart company focused on developing science-driven solutions for cardiac care. The company's work centers on restoring heart valve patients to healthy function through advancements in tissue engineering, biomimetic valve technology, and anti-calcification technology.

The company's primary product is the DurAVR Transcatheter Heart Valve (THV). This device is described as a first-of-its-kind biomimetic TAVR valve built with proprietary ADAPT anti-calcification technology, designed to mimic the heart's native physiology. It has been clinically proven to remain calcium-free for up to 10 years.

Anteris Technologies' patented anti-calcification tissue has been used in over 55,000 patients worldwide. The company maintains a presence in Brisbane and Perth, Australia; Minneapolis, Minnesota; and Geneva, Switzerland.